DA-9601, a Food and Drug Administration-approved drug that comprises eupatilin as an active ingredient, was developed as a clinical therapeutic agent for asthma treatment due to its capability of suppressing the airway allergic inflammation via regulation of various cellular molecules expressed by the MAP kinases/NF-κB pathway (Kim et al., 2006). The gene discussed is NFKB1; the disease is asthma.